Search

Your search keyword '"D'Ambrosio, Daniele"' showing total 278 results
Start Over Author "D'Ambrosio, Daniele"
278 results on '"D'Ambrosio, Daniele"'

3. Results of an observational retrospective multicenter study: “Campania INternal medicine - the Clinical INternist for heart failure”

Author

Gallucci, Fernando, primary, Marrone, Emiliana, additional, Nappi, Roberto, additional, Renis, Maurizio, additional, Coppola, Maria Gabriella, additional, Ciarambino, Tiziana, additional, D’Ambrosio, Daniele, additional, Maffettone, Ada, additional, D’Avino, Maria, additional, and For HF Group Researchers, CIN CIN, additional

Published
2023
Full Text
View/download PDF

11. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial

Author

Kappos, Ludwig, Fox, Robert J., Burcklen, Michel, Freedman, Mark S., Kubala Havrdova, Eva, Hennessy, Brian, Hohlfeld, Reinhard, Lublin, Fred, Montalban, Xavier, Pozzilli, Carlo, Scherz, Tatiana, D'Ambrosio, Daniele, Linscheid, Philippe, Vaclavkova, Andrea, Pirozek-Lawniczek, Magdalena, Kracker, Hilke, Sprenger, Till, and Universitat Autònoma de Barcelona

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Toluidines, Hydroxybutyrates, law.invention, 03 medical and health sciences, chemistry.chemical_compound, Young Adult, 0302 clinical medicine, Multiple Sclerosis, Relapsing-Remitting, Randomized controlled trial, law, Internal medicine, Teriflunomide, Nitriles, medicine, Clinical endpoint, Humans, Immunologic Factors, 030212 general & internal medicine, Original Investigation, Expanded Disability Status Scale, business.industry, Multiple sclerosis, McDonald criteria, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Thiazoles, chemistry, Ponesimod, Tolerability, Crotonates, Disease Progression, Female, Neurology (clinical), Neoplasm Recurrence, Local, business, 030217 neurology & neurosurgery, medicine.drug
Abstract

IMPORTANCE: To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis (RMS). OBJECTIVE: To compare the efficacy of ponesimod, a selective sphingosine-1-phosphate receptor 1 (S1P(1)) modulator with teriflunomide, a pyrimidine synthesis inhibitor, approved for the treatment of patients with RMS. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, active-comparator, superiority randomized clinical trial enrolled patients from April 27, 2015, to May 16, 2019, who were aged 18 to 55 years and had been diagnosed with multiple sclerosis per 2010 McDonald criteria, with a relapsing course from the onset, Expanded Disability Status Scale (EDSS) scores of 0 to 5.5, and recent clinical or magnetic resonance imaging disease activity. INTERVENTIONS: Patients were randomized (1:1) to 20 mg of ponesimod or 14 mg of teriflunomide once daily and the placebo for 108 weeks, with a 14-day gradual up-titration of ponesimod starting at 2 mg to mitigate first-dose cardiac effects of S1P(1) modulators and a follow-up period of 30 days. MAIN OUTCOMES AND MEASURES: The primary end point was the annualized relapse rate. The secondary end points were the changes in symptom domain of Fatigue Symptom and Impact Questionnaire–Relapsing Multiple Sclerosis (FSIQ–RMS) at week 108, the number of combined unique active lesions per year on magnetic resonance imaging, and time to 12-week and 24-week confirmed disability accumulation. Safety and tolerability were assessed. Exploratory end points included the percentage change in brain volume and no evidence of disease activity (NEDA-3 and NEDA-4) status. RESULTS: For 1133 patients (567 receiving ponesimod and 566 receiving teriflunomide; median [range], 37.0 [18-55] years; 735 women [64.9%]), the relative rate reduction for ponesimod vs teriflunomide in the annualized relapse rate was 30.5% (0.202 vs 0.290; P

Published
2021

12. Natural History of Scoliosis in Children with NF1: An Observation Study

Author

Toro, Giuseppe, primary, Santoro, Claudia, additional, Ambrosio, Daniele, additional, Landi, Giovanni, additional, Scilipoti, Martina, additional, Moretti, Antimo, additional, Paoletta, Marco, additional, Liguori, Sara, additional, Schiavone Panni, Alfredo, additional, Picariello, Stefania, additional, and Iolascon, Giovanni, additional

Published
2021
Full Text
View/download PDF

13. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study

Author

Kappos, Ludwig, primary, Fox, Robert J., additional, Burcklen, Michel, additional, Freedman, Mark S., additional, Havrdová, Eva K., additional, Hennessy, Brian, additional, Hohlfeld, Reinhard, additional, Lublin, Fred, additional, Montalban, Xavier, additional, Pozzilli, Carlo, additional, Scherz, Tatiana, additional, D'Ambrosio, Daniele, additional, Linscheid, Philippe, additional, Vaclavkova, Andrea, additional, Pirozek-Lawniczek, Magdalena, additional, Kracker, Hilke, additional, and Sprenger, Till, additional

Published
2021
Full Text
View/download PDF

16. Fractures around Trochanteric Nails: The “Vergilius Classification System”

Author

Toro, Giuseppe, primary, Moretti, Antimo, additional, Ambrosio, Daniele, additional, Pezzella, Raffaele, additional, De Cicco, Annalisa, additional, Landi, Giovanni, additional, Tammaro, Nicola, additional, Florio, Pasquale, additional, Cecere, Antonio Benedetto, additional, Braile, Adriano, additional, Medici, Antonio, additional, Siano, Antonio, additional, Di Maggio, Bruno, additional, Calabrò, Giampiero, additional, Gagliardo, Nicola, additional, Di Fino, Ciro, additional, Bruno, Gaetano, additional, Pellegrino, Achille, additional, Negri, Giacomo, additional, Monaco, Vincenzo, additional, Gison, Michele, additional, Toro, Antonio, additional, Schiavone Panni, Alfredo, additional, Tarantino, Umberto, additional, and Iolascon, Giovanni, additional

Published
2021
Full Text
View/download PDF

20. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

Author

Ruperto, Nicolino, Quartier, Pierre, Wulffraat, Nico, Woo, Patricia, Ravelli, Angelo, Mouy, Richard, Bader-Meunier, Brigitte, Vastert, Sebastiaan J., Noseda, Emanuele, DʼAmbrosio, Daniele, Lecot, Jean, Chakraborty, Abhijit, Martini, Alberto, and Chioato, Andrea

Published
2012
Full Text
View/download PDF

27. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by FcGammaRIIB1

Author

D'Ambrosio, Daniele, Hippen, Keli L., Minskoff, Stacey A., Mellman, Ira, Pani, Giovanni, Siminovitch, Kathy A., and Cambier, John C.

Subjects
Autoimmunity -- Research, Cellular signal transduction -- Research, Fc receptors -- Research, Science and technology, Research
Abstract

Coligation of the Fc receptor on B cells, FcγRIIB1, with the B cell antigen receptor (BCR) leads to abortive BCR signaling. Here it was shown that the FcγRIIB1 recruits the phosphotyrosine phosphatase PTP1C after BCR coligation. This association is mediated by the binding of a 13-amino acid tyrosine-phosphorylated sequence to the carboxyl-terminal Src homology 2 domain of PTP1C and activates PTP1C.Inhibitory signaling and PTP1C recruitment are dependent on the presence of the tyrosine within the 13-amino acid sequence. Inhibitory signaling mediated by FcγRIIB1 is deficient in motheaten mice which do not express functional PTP1C. Thus, PTP1C is an effector of BCR-FcγRIIB1 negative signal cooperativity., For decades it has been known that immune complexes consisting of antigen and immunoglobulin G (IgG) antibodies are potent inhibitors of humoral immune responses (1). Immune complex-mediated inhibition of antibody [...]

Published
1995

38. Efficacy and Safety of 2 Doses of Ponesimod (10 and 20 mg o.d.): Interim Analysis of a Phase II Extension Trial in Relapsing-remitting Multiple Sclerosis (P3.398)

Author

Havrdová, Eva, primary, Achiron, Anat, additional, Coyle, Patricia, additional, D’Ambrosio, Daniele, additional, Erälinna, Juha-Pekka, additional, Hennessy, Brian, additional, Lindenstroem, Ewa, additional, Lycke, Jan, additional, Izquierdo, Guillermo, additional, Pozzilli, Carlo, additional, and Freedman, Mark, additional

Published
2018
Full Text
View/download PDF

41. Effects of multiple-dose ponesimod, a selective S1P1 receptor modulator, on lymphocyte subsets in healthy humans

Author

Jurcevic,Stipo, Juif,Pierre-Eric, Hamid,Colleen, Greenlaw,Roseanna, D'Ambrosio,Daniele, Dingemanse,Jasper, Jurcevic,Stipo, Juif,Pierre-Eric, Hamid,Colleen, Greenlaw,Roseanna, D'Ambrosio,Daniele, and Dingemanse,Jasper

Abstract

Stipo Jurcevic,1 Pierre-Eric Juif,2 Colleen Hamid,3 Roseanna Greenlaw,3 Daniele D’Ambrosio,2 Jasper Dingemanse2 1Department of Biomedical Sciences, University of Westminster, London, UK; 2Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; 3Division of Transplantation Immunology & Mucosal Biology, King’s College London, London, UK Abstract: This study investigated the effects of ponesimod, a selective S1P1 receptor modulator, on T lymphocyte subsets in 16 healthy subjects. Lymphocyte subset proportions and absolute numbers were determined at baseline and on Day 10, after once-daily administration of ponesimod (10 mg, 20 mg, and 40 mg each consecutively for 3 days) or placebo (ratio 3:1). The overall change from baseline in lymphocyte count was -1,292±340×106 cells/L and 275±486×106 cells/L in ponesimod- and placebo-treated subjects, respectively. This included a decrease in both T and B lymphocytes following ponesimod treatment. A decrease in naïve CD4+ T cells (CD45RA+CCR7+) from baseline was observed only after ponesimod treatment (-113±98×106 cells/L, placebo: 0±18×106 cells/L). The number of T-cytotoxic (CD3+CD8+) and T-helper (CD3+CD4+) cells was significantly altered following ponesimod treatment compared with placebo. Furthermore, ponesimod treatment resulted in marked decreases in CD4+ T-central memory (CD45RA-CCR7+) cells (-437±164×106 cells/L) and CD4+ T-effector memory (CD45RA-CCR7-) cells (-131±57×106 cells/L). In addition, ponesimod treatment led to a decrease of -228±90×106 cells/L of gut-homing T cells (CLA-integrin β7+). In contrast, when compared with placebo, CD8+ T-effector memory and natural killer (NK) cells wer

Published
2016

42. Does comprehensive geriatric assessment improve the estimate of surgical risk in elderly patients? An Italian multicenter observational study

Author

Abete, Pasquale, primary, Cherubini, Antonio, additional, Di Bari, Mauro, additional, Vigorito, Carlo, additional, Viviani, Giorgio, additional, Marchionni, Niccolò, additional, D'Ambrosio, Daniele, additional, Golino, Alessandro, additional, Serra, Rocco, additional, Zampi, Elena, additional, Bracali, Ilaria, additional, Mello, AnnaMaria, additional, Vitelli, Alessandra, additional, Rengo, Giuseppe, additional, Cacciatore, Francesco, additional, and Rengo, Franco, additional

Published
2016
Full Text
View/download PDF

49. Helicobacter pylori-Induced Interleukin-12 p40 Expression

Author

Takeshima, Eriko, Tomimori, Koh, Teruya, Hiromitsu, Ishikawa, Chie, Senba, Masachika, D' Ambrosio, Daniele, Kinjo, Fukunori, Mimuro, Hitomi, Sasakawa, Chihiro, Hirayama, Toshiya, Fujita, Jiro, Mori, Naoki, Takeshima, Eriko, Tomimori, Koh, Teruya, Hiromitsu, Ishikawa, Chie, Senba, Masachika, D' Ambrosio, Daniele, Kinjo, Fukunori, Mimuro, Hitomi, Sasakawa, Chihiro, Hirayama, Toshiya, Fujita, Jiro, and Mori, Naoki

Abstract

Interleukin-12 (IL-12) is a heterodimeric cytokine produced by antigen-presenting cells that promotes the development of T-helper lymphocyte 1 (Th1). Chronic gastritis induced by Helicobacter pylori is considered a Th1-mediated process. IL-12 levels in gastric biopsy samples of H. pylori-infected patients are higher than in those of uninfected individuals, but the cellular source of IL-12 remains elusive. IL-12 staining was detected in mucosal epithelial cells, lymphocytes, and macrophages in specimens of patients with H. pylori-positive gastritis. Therefore, we investigated IL-12 p40 mRNA induction by H. pylori in gastric epithelial cells and T cells. Although cag pathogenicity island (PAI)-positive H. pylori induced IL-12 p40 mRNA expression, an isogenic mutant of the cag PAI failed to induce it in both cell types. Supernatants from H. pylori cultures and H. pylori VacA induced IL-12 p40 mRNA expression in T cells but not in epithelial cells. The activation of the IL-12 p40 promoter by H. pylori was mediated through NF-κB. The transfection of IκB kinase and NF-κB-inducing kinase dominant-negative mutants inhibited H. pylori-induced IL-12 p40 activation. Inhibitors of NF-κB, phosphatidylinositol 3-kinase, p38 mitogen-activated protein kinase, and Hsp90 suppressed H. pylori- and VacA-induced IL-12 p40 mRNA expression. The results indicate that H. pylori induces IL-12 p40 expression by the activation of NF-κB, phosphatidylinositol 3-kinase, and p38 mitogen-activated protein kinase. Hsp90 is also a crucial regulator of H. pylori-induced IL-12 p40 expression. In addition to the cag PAI, VacA might be relevant in the induction of IL-12 expression and a Th1-polarized response only in T cells.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results